Lokon Pharma AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Private
- Established
- 2015-01-01
- Employees
- 1
- Market Cap
- -
- Website
- https://lokonpharma.com
A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-10-11
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Lokon Pharma AB
- Target Recruit Count
- 26
- Registration Number
- NCT04123470
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸Baylor St Luke's Medical Center, Houston, Texas, United States
🇸🇪Uppsala University Hospital, Uppsala, Sweden
Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Lokon Pharma AB
- Target Recruit Count
- 47
- Registration Number
- NCT03225989
- Locations
- 🇸🇪
Karolinska University Hospital, Huddinge, Stockholm, Sweden
🇸🇪Uppsala University Hospital, Uppsala, Sweden
LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2016-03-10
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Lokon Pharma AB
- Target Recruit Count
- 55
- Registration Number
- NCT02705196
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸Baylor St Luke's Medical Center, Houston, Texas, United States
© Copyright 2024. All Rights Reserved by MedPath